GlaxoSmithKline (GSK) closed at $45.06 in the latest trading session, marking a -0.4% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.42%. At the same time, the Dow lost 0.49%, and the tech-heavy Nasdaq lost 0.47%.Prior to today's trading, shares of the drug developer had gained 3.62% over the past month. This has outpaced the Medical sector's loss of 1.69% and the S&P 500's gain of 0.39% in that time.GlaxoSmithKline will be looking to display strength as it nears its next earnings release. On that day, GlaxoSmithKline is projected to report earnings of $0.61 per share, which would represent a year-over-year decline of 1.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.22 billion, up 5.83% from the year-ago period.Any recent changes to analyst estimates for GlaxoSmithKline should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.81% lower. GlaxoSmithKline is holding a Zacks Rank of #3 (Hold) right now.Digging into valuation, GlaxoSmithKline currently has a Forward P/E ratio of 14.04. This valuation marks a premium compared to its industry's average Forward P/E of 13.04.Investors should also note that GSK has a PEG ratio of 3.01 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.01 based on yesterday's closing prices.The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 210, which puts it in the bottom 18% of all 250+ industries.The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow GSK in the coming trading sessions, be sure to utilize Zacks.com. Bitcoin, Like the Internet Itself, Could Change Everything Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities. Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly. See 3 crypto-related stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report To read this article on Zacks.com click here.